Migraine Drugs Market by Type (Abortive Medicine, Preventive Medicine), Administration Route (Oral, Injection, Others), Distribution Channel (Hospital-based Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Opportunity Analysis and Industry
Request Sample
Pre-order Enquiry
Request Customization
Check Discounts
The Global Migraine Drugs Market size was valued at USD 1.80 billion in 2019 and is predicted to reach USD 2.44 billion by 2030, with a CAGR of 2.8% from 2020-2030.
Migraine is a medical condition pertaining with primary headache disorder with symptoms such as nausea, vomiting, dry mouth, somnolence, and sensitivity to light or sound. The headaches start from one side of the head and are pulsating in nature. In some cases, patients are affected by prevalence of aura.
The recurrent headaches can last up to some hours or days, with intensity varying from moderate to severe. Migraine has no permanent cure, but migraine drugs can be used to reduce and prevent migraines.
Women are more prone to migraine attacks due to conditions like; menstrual migraines, menopause migraines, and migraines due to stress, hypertension, or other hormonal issues. The increasing prevalence of migraine, specifically in women as compared to men, raises the demand for effective migraine drugs, thereby propagating the growth of global migraine drugs market.
Market Dynamics and Trends
According to the data provided by Migraine Trust in 2017, 1 in 7 people worldwide suffer from migraine, i.e. 2% of the total world population suffer from migraine; thereby, migraine being the third most common disease at global level. This scenario generates a demand for effective migraine drugs with minimal or no side-effects; hence supplementing the growth of migraine drugs market.
However, side effects associated with the intake of migraine drugs are expected to restrict the growth of migraine drugs market.
Moreover, the factors such as growing consumer awareness regarding better treatment options, increasing number of approvals granted by the U.S Food and Drug Administration, and upsurge in investments for R&D activities, are anticipated in creating several profitable opportunities for the growth of global migraine drugs market, in coming future.
Market Segmentations and Scope of the Study:
The global migraine drugs market share has been analyzed based on type, route of administration, distribution channel and geography.
Based on type, the migraine drugs market is segmented into preventive medicine and abortive medicine. The abortive medicine segment is sub segmented into Triptans (Serotonin Receptor Agonists), Ergotamine Derivative, and others. The preventive medicine is further divided into Anticonvulsant, Antidepressant, Beta Blocker, and others. Based on distribution channel, the migraine drugs market is divided into hospital-based pharmacies, retail pharmacies, and online pharmacies. Geographic breakdown and analysis of each of the previously mentioned segments include regions comprising North America, Europe, Asia-Pacific, and RoW.
Geographical Analysis
North America denotes higher adoption of the migraine drugs and is anticipated to hold the highest market share in the global migraine drugs market throughout the forecast period. This is attributable to the factors including presence of well-established healthcare amenities, increased awareness among people, and advancements in medical technologies.
Asia Pacific is estimated to show rapid growth with developing market size, owing to increasing accessibility to healthcare facilities, and increased investment by the market players especially in the emerging economies.
The migraine drugs market is highly competitive and consists of various market players. Some of the major market players include Allergan Plc., Abbott Laboratories, AstraZeneca, Endo International Plc., Eisai Co. Ltd., Impax Laboratories, GlaxoSmithKline Plc., Johnson & Johnson, Pfizer Inc., Merck & Co., Teva Pharmaceutical Industries Limited, Sanofi SA, and Novartis International AG, among others.
An upsurge in R&D activities and increasing approvals granted by the U.S Food and Drug Administration (FDA), for new products launched by the key players, is leading the healthcare industry to new heights, thereby creating lucrative opportunities in the global migraine drugs market.
For instance, in January 2020, Ubrogepant commercialized as Ubrelvy in the migraine drugs market was granted the FDA approval, for treating patients suffering from acute migraine with or without the prevalence of aura in adults. Ubrogepant as compared to its antagonist placebo gives fast relief from migraine symptoms such as nausea, vomiting, dry mouth, somnolence, and sensitivity to light or sound; within 2 hours of intake.
In February 2020, Biohaven announced that its NURTEC ODT-Rimegepant drug got approved by the U.S FDA, for treatment of acute migraine in adults. The studies claimed that a single oral dose of 75 mg NURTEC ODT, can provide relief to patients suffering from acute migraine condition within an hour, and its effect lasts for about 48 hours. The first-ever Calcitonin Gene-Related Peptide (CGRP) receptors, are orally dispersible tablets, that can be taken with or without water. These are known to provide fast relief even in acute migraine conditions.
In February 2020, Lundbeck, a well-known player in the migraine drugs market announced that its drug VYEPTI- eptinezumab-jjmr, got approved by the U.S FDA, for prevention and treatment of migraine in adults. VYEPTI is the first-ever intravenous (IV) treatment for migraine prevention. The clinical studies represented migraine reduction by 75% in 6 months, with a recommended dosage of 100 mg every 3 months
KEY MARKET SEGMENTS:
Global Migraine Drugs market –
Abortive Medicine
Triptans (Serotonin Receptor Agonists)
Ergotamine Derivative
Others
Preventive Medicine
Anticonvulsant
Antidepressant
Beta Blocker
Others
Global Migraine Drugs market – By Route of Administration
Oral
Injection
Others
Global Migraine Drugs market –By Distribution Channel
Hospital-based Pharmacies
Retail Pharmacies
Online Pharmacies
Global Migraine Drugs market –By Geography
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
India
Japan
Australia
South Korea
Rest of Asia-Pacific
RoW
Saudi Arabia
South Africa
Brazil
Remaining countries
Migraine is a medical condition pertaining with primary headache disorder with symptoms such as nausea, vomiting, dry mouth, somnolence, and sensitivity to light or sound. The headaches start from one side of the head and are pulsating in nature. In some cases, patients are affected by prevalence of aura.
The recurrent headaches can last up to some hours or days, with intensity varying from moderate to severe. Migraine has no permanent cure, but migraine drugs can be used to reduce and prevent migraines.
Women are more prone to migraine attacks due to conditions like; menstrual migraines, menopause migraines, and migraines due to stress, hypertension, or other hormonal issues. The increasing prevalence of migraine, specifically in women as compared to men, raises the demand for effective migraine drugs, thereby propagating the growth of global migraine drugs market.
Market Dynamics and Trends
According to the data provided by Migraine Trust in 2017, 1 in 7 people worldwide suffer from migraine, i.e. 2% of the total world population suffer from migraine; thereby, migraine being the third most common disease at global level. This scenario generates a demand for effective migraine drugs with minimal or no side-effects; hence supplementing the growth of migraine drugs market.
However, side effects associated with the intake of migraine drugs are expected to restrict the growth of migraine drugs market.
Moreover, the factors such as growing consumer awareness regarding better treatment options, increasing number of approvals granted by the U.S Food and Drug Administration, and upsurge in investments for R&D activities, are anticipated in creating several profitable opportunities for the growth of global migraine drugs market, in coming future.
Market Segmentations and Scope of the Study:
The global migraine drugs market share has been analyzed based on type, route of administration, distribution channel and geography.
Based on type, the migraine drugs market is segmented into preventive medicine and abortive medicine. The abortive medicine segment is sub segmented into Triptans (Serotonin Receptor Agonists), Ergotamine Derivative, and others. The preventive medicine is further divided into Anticonvulsant, Antidepressant, Beta Blocker, and others. Based on distribution channel, the migraine drugs market is divided into hospital-based pharmacies, retail pharmacies, and online pharmacies. Geographic breakdown and analysis of each of the previously mentioned segments include regions comprising North America, Europe, Asia-Pacific, and RoW.
Geographical Analysis
North America denotes higher adoption of the migraine drugs and is anticipated to hold the highest market share in the global migraine drugs market throughout the forecast period. This is attributable to the factors including presence of well-established healthcare amenities, increased awareness among people, and advancements in medical technologies.
Asia Pacific is estimated to show rapid growth with developing market size, owing to increasing accessibility to healthcare facilities, and increased investment by the market players especially in the emerging economies.
Competitive Landscape
The migraine drugs market is highly competitive and consists of various market players. Some of the major market players include Allergan Plc., Abbott Laboratories, AstraZeneca, Endo International Plc., Eisai Co. Ltd., Impax Laboratories, GlaxoSmithKline Plc., Johnson & Johnson, Pfizer Inc., Merck & Co., Teva Pharmaceutical Industries Limited, Sanofi SA, and Novartis International AG, among others.
An upsurge in R&D activities and increasing approvals granted by the U.S Food and Drug Administration (FDA), for new products launched by the key players, is leading the healthcare industry to new heights, thereby creating lucrative opportunities in the global migraine drugs market.
For instance, in January 2020, Ubrogepant commercialized as Ubrelvy in the migraine drugs market was granted the FDA approval, for treating patients suffering from acute migraine with or without the prevalence of aura in adults. Ubrogepant as compared to its antagonist placebo gives fast relief from migraine symptoms such as nausea, vomiting, dry mouth, somnolence, and sensitivity to light or sound; within 2 hours of intake.
In February 2020, Biohaven announced that its NURTEC ODT-Rimegepant drug got approved by the U.S FDA, for treatment of acute migraine in adults. The studies claimed that a single oral dose of 75 mg NURTEC ODT, can provide relief to patients suffering from acute migraine condition within an hour, and its effect lasts for about 48 hours. The first-ever Calcitonin Gene-Related Peptide (CGRP) receptors, are orally dispersible tablets, that can be taken with or without water. These are known to provide fast relief even in acute migraine conditions.
In February 2020, Lundbeck, a well-known player in the migraine drugs market announced that its drug VYEPTI- eptinezumab-jjmr, got approved by the U.S FDA, for prevention and treatment of migraine in adults. VYEPTI is the first-ever intravenous (IV) treatment for migraine prevention. The clinical studies represented migraine reduction by 75% in 6 months, with a recommended dosage of 100 mg every 3 months
KEY MARKET SEGMENTS:
Global Migraine Drugs market –
By Type
Abortive Medicine
Triptans (Serotonin Receptor Agonists)
Ergotamine Derivative
Others
Preventive Medicine
Anticonvulsant
Antidepressant
Beta Blocker
Others
Global Migraine Drugs market – By Route of Administration
Oral
Injection
Others
Global Migraine Drugs market –By Distribution Channel
Hospital-based Pharmacies
Retail Pharmacies
Online Pharmacies
Global Migraine Drugs market –By Geography
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
India
Japan
Australia
South Korea
Rest of Asia-Pacific
RoW
Saudi Arabia
South Africa
Brazil
Remaining countries
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Details
NMS-18644780
01-Mar-2020
408
01-Mar-2020
408
License
